Literature DB >> 30610085

Membrane-Anchored Serine Proteases and Protease-Activated Receptor-2-Mediated Signaling: Co-Conspirators in Cancer Progression.

Nisha R Pawar1,2, Marguerite S Buzza1,2,3, Toni M Antalis4,2,3.   

Abstract

Pericellular proteolysis provides a significant advantage to developing tumors through the ability to remodel the extracellular matrix, promote cell invasion and migration, and facilitate angiogenesis. Recent advances demonstrate that pericellular proteases can also communicate directly to cells by activation of a unique group of transmembrane G-protein-coupled receptors (GPCR) known as protease-activated receptors (PAR). In this review, we discuss the specific roles of one of four mammalian PARs, namely PAR-2, which is overexpressed in advanced stage tumors and is activated by trypsin-like serine proteases that are highly expressed or otherwise dysregulated in many cancers. We highlight recent insights into the ability of different protease agonists to bias PAR-2 signaling and the newly emerging evidence for an interplay between PAR-2 and membrane-anchored serine proteases, which may co-conspire to promote tumor progression and metastasis. Interfering with these pathways might provide unique opportunities for the development of new mechanism-based strategies for the treatment of advanced and metastatic cancers. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30610085      PMCID: PMC6335149          DOI: 10.1158/0008-5472.CAN-18-1745

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  152 in total

1.  Transport via the transcytotic pathway makes prostasin available as a substrate for matriptase.

Authors:  Stine Friis; Sine Godiksen; Jette Bornholdt; Joanna Selzer-Plon; Hanne Borger Rasmussen; Thomas H Bugge; Chen-Yong Lin; Lotte K Vogel
Journal:  J Biol Chem       Date:  2010-12-10       Impact factor: 5.157

2.  Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain.

Authors:  Ming-Shyue Lee; I-Chu Tseng; Youhong Wang; Ken-ichi Kiyomiya; Michael D Johnson; Robert B Dickson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2007-03-07       Impact factor: 4.249

3.  Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells.

Authors:  K Shigemasa; L J Underwood; J Beard; H Tanimoto; K Ohama; T H Parmley; T J O'Brien
Journal:  J Soc Gynecol Investig       Date:  2000 Nov-Dec

4.  A mouse serine protease TESP5 is selectively included into lipid rafts of sperm membrane presumably as a glycosylphosphatidylinositol-anchored protein.

Authors:  Arata Honda; Kazuo Yamagata; Shin Sugiura; Katsuto Watanabe; Tadashi Baba
Journal:  J Biol Chem       Date:  2002-02-22       Impact factor: 5.157

5.  Local protease signaling contributes to neural tube closure in the mouse embryo.

Authors:  Eric Camerer; Adrian Barker; Daniel N Duong; Rajkumar Ganesan; Hiroshi Kataoka; Ivo Cornelissen; Molly R Darragh; Arif Hussain; Yao-Wu Zheng; Yoga Srinivasan; Christopher Brown; Shan-Mei Xu; Jean B Regard; Chen-Yong Lin; Charles S Craik; Daniel Kirchhofer; Shaun R Coughlin
Journal:  Dev Cell       Date:  2010-01-19       Impact factor: 12.270

Review 6.  Matriptase and its putative role in cancer.

Authors:  K Uhland
Journal:  Cell Mol Life Sci       Date:  2006-12       Impact factor: 9.261

7.  A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation.

Authors:  Stine Friis; Katiuchia Uzzun Sales; Sine Godiksen; Diane E Peters; Chen-Yong Lin; Lotte K Vogel; Thomas H Bugge
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

8.  Reduced prostasin (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matriptase activation.

Authors:  Roman Szabo; Katiuchia Uzzun Sales; Peter Kosa; Natalia A Shylo; Sine Godiksen; Karina K Hansen; Stine Friis; J Silvio Gutkind; Lotte K Vogel; Edith Hummler; Eric Camerer; Thomas H Bugge
Journal:  PLoS Genet       Date:  2012-08-30       Impact factor: 5.917

9.  The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.

Authors:  Ayala Tamir; Anju Gangadharan; Sakshi Balwani; Takemi Tanaka; Ushma Patel; Ahmed Hassan; Stephanie Benke; Agnieszka Agas; Joseph D'Agostino; Dayoung Shin; Sunghoon Yoon; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Ovarian Res       Date:  2016-03-31       Impact factor: 4.234

10.  The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.

Authors:  Shang-Ru Wu; Chen-Hsin Teng; Ya-Ting Tu; Chun-Jung Ko; Tai-Shan Cheng; Shao-Wei Lan; Hsin-Ying Lin; Hsin-Hsien Lin; Hsin-Fang Tu; Pei-Wen Hsiao; Hsiang-Po Huang; Chung-Hsin Chen; Ming-Shyue Lee
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

View more
  12 in total

1.  Iterative, multiplexed CRISPR-mediated gene editing for functional analysis of complex protease gene clusters.

Authors:  LuLu K Callies; Daniel Tadeo; Jan Simper; Thomas H Bugge; Roman Szabo
Journal:  J Biol Chem       Date:  2019-09-09       Impact factor: 5.157

2.  Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression.

Authors:  Candy M Rivas; Hillary V Schiff; Aubin Moutal; Rajesh Khanna; Pawel R Kiela; Gregory Dussor; Theodore J Price; Josef Vagner; Kathryn A DeFea; Scott Boitano
Journal:  Biochem Biophys Res Commun       Date:  2021-12-29       Impact factor: 3.575

3.  Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.

Authors:  Nadire Duru; Nisha R Pawar; Erik W Martin; Marguerite S Buzza; Gregory D Conway; Rena G Lapidus; Shihui Liu; Jocelyn Reader; Gautam G Rao; Dana M Roque; Stephen H Leppla; Toni M Antalis
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

4.  Treatment of ovarian cancer with modified anthrax toxin.

Authors:  Klaus Aktories
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-02       Impact factor: 12.779

5.  Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation.

Authors:  Yuhong Jiang; Xin Zhuo; Xiujuan Fu; Yue Wu; Canquan Mao
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 6.  The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.

Authors:  Lukas Wettstein; Frank Kirchhoff; Jan Münch
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

Review 7.  Pancreatic Proteolytic Enzymes and Cancer: New Support for an Old Theory.

Authors:  Linda L Isaacs
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

8.  Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019.

Authors:  Saravanan Subramaniam; Wolfram Ruf; Markus Bosmann
Journal:  Br J Pharmacol       Date:  2021-07-07       Impact factor: 8.739

Review 9.  Is There a Trojan Horse to Aggressive Pancreatic Cancer Biology? A Review of the Trypsin-PAR2 Axis to Proliferation, Early Invasion, and Metastasis.

Authors:  Kjetil Søreide; Marcus Roalsø; Jan Rune Aunan
Journal:  J Pancreat Cancer       Date:  2020-02-06

10.  Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer.

Authors:  Qianfei Liu; Jianbo He; Ruiling Ning; Liping Tan; Aiping Zeng; Shaozhang Zhou
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.